VPRIV® (velaglucerase alfa for injection) logo
Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Important Safety Information: Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV should be administered under the supervision of a healthcare professional. Read more Important Safety Information

Additional Support


Streamlining the start of your treatment

  Starting VPRIV® treatment

When starting VPRIV — whether you’re new to enzyme replacement therapy (ERT) altogether or just switching over from another treatment — there may be some administrative hurdles with insurance. One of the most commonly encountered issues that has the potential to delay the start of your treatment is called a prior authorization (PA).

Starting VPRIV® treatment

A prior authorization is when your insurance company requires your doctor to fill out some additional paperwork before your prescription is processed. This can delay you from starting treatment while your paperwork is being evaluated and processed.

Our QuickStart program helps you avoid treatment start delays during the PA process, by allowing you to receive:

  • your first infusion while this prior authorization is still being reviewed
  • one free dose of VPRIV, if eligible and prescribed by your doctor

Additional terms and conditions may apply.


expediting the infusion preparation

What many patients don’t know when starting ERT is that it takes time for their site of care to prepare infusions. In order to prevent a long wait before your infusion begins, talk to your OnePath® Patient Support Manager about PreppedAhead.

PREPPEDAHEAD™: expediting infusion preparation PREPPEDAHEAD™: expediting infusion preparation

PreppedAhead is a program that provides you with the option of having the site of care prepare your treatment before you arrive — so you don’t have to wait as long before your infusion begins.

This service is available only to patients enrolled in OnePath and sites of care that are enrolled in the PreppedAhead program.

Support from patients living with type 1 Gaucher

Get support from others like you.

You’re not alone. Hear from others living with type 1 Gaucher.

Check out
their stories
Type 1 Gaucher resources and organizations

What other resources are available?

There are several organizations dedicated to type 1 Gaucher.

Connect with
them here


VPRIV® (velaglucerase alfa for injection) is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.


  • Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV should be administered under the supervision of a healthcare professional. VPRIV is given every other week by intravenous infusion that typically takes up to 60 minutes. Appropriate medical support should be available when VPRIV is administered. The most serious side effects in patients treated with VPRIV were hypersensitivity reactions.
  • Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.
  • If anaphylactic or other acute reactions occur, your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.
  • The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.
  • Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
  • The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.
  • The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.
  • As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.
  • Please see full Prescribing Information.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You are about
to leave this site.

You are being directed to another site.

Please be advised that Shire may not have control over the content or presentation of the site you are about to view.

Back Continue

You are about
to leave this site.

You are being directed to another site.

The information contained in this section of the site is intended for US health care professionals only. Click Continue if you are a health care professional.

Back Continue